Major neutralization site of hepatitis e virus and use of this neutralization site in methods of vaccination and in methods of screening for neutralizing antibodies to hepatitis e virus
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsDarren Schofield, Suzanne U. Emerson, Robert H. Purcell
Life of this patent
Estimating the term…
Abstract
The invention describes the identification of major neutralization site of hepatitis E virus (HEV) and the use of this neutralization site in methods of vaccination and in methods of screening for neutralizing antibodies to HEV. The invention also describes the isolation and characterization of neutralizing chimpanzee monoclonal antibodies reactive to the neutralization site and the use of these antibodies in the diagnosis, treatment and prevention of HEV.
Claims30
A polypeptide of about 30 amino acids in length, spanning from amino acids 572 to 607 of the open-reading frame 2 gene of a hepatitis E virus, wherein the polypeptide is a neutralization site for hepatitis E virus.
A monoclonal antibody having CDR3 sequence selected from the CDR3 sequences shown in FIG. 8.
Dependencies are inferred from the claim text.